Neoplasms — BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer
Citation(s)
An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Maximum Tolerated Dose and Biomarker Response After Intravenous Administration of Weekly BAY80-6946 to Patients With Advanced Cancer